Clinical Trial Update: Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

A Phase 3 bioequivalence study comparing pimecrolimus 1% cream to Elidel 1% cream in mild to moderate atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Elidel® Cream, 1% (pimecrolimus)
• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Mylan Inc. | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2020-03-17